Tandem Diabetes Care, Inc. recalls Tandem Mobi Insulin Pump with Interoperable Technology

Recall date

February 27, 2025

Source

U.S. Food & Drug Administration (FDA) — enforcement report

Recall number

Z-1520-2025

FDA classification

Class I

Brand / firm

Tandem Diabetes Care, Inc.

Sold / distributed

US: AZ, CA, CO, CT, FL, HI, IA, ID, IL, IN, MD, ME, MI, MO, MS, NC, ND, NE, NJ, NM, NV, NY, OH, PA, TX, UT, VA, WA, WI OUS: N/A

Why it was recalled

A software defect in Version 7.9 of the pump software for Tandem t:slim X2 and Tandem Mobi pumps, when used with Control IQ+ technology, will cause the pump to incorrectly interpolate glucose trends when the Estimated Glucose Value (EGV) is above 255 mg/dL at the start or end of a gap in data collection due to a lapse in connection from a paired continuous glucose monitor (CGM) sensor, which can lead to under-delivery or over-delivery of insulin based on inaccurate result leading to severe cases of hypoglycemia or hyperglycemia.

Class I is the FDA’s most serious recall level: there is a reasonable probability that using this product will cause serious harm or death.

What was recalled

Tandem Mobi Insulin Pump with Interoperable Technology